(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 8.56% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.35%.
Zoetis's revenue in 2023 is $8,007,000,000.On average, 6 Wall Street analysts forecast ZTS's revenue for 2023 to be $4,150,159,052,717, with the lowest ZTS revenue forecast at $4,029,658,468,770, and the highest ZTS revenue forecast at $4,221,544,969,831. On average, 6 Wall Street analysts forecast ZTS's revenue for 2024 to be $4,476,569,311,912, with the lowest ZTS revenue forecast at $4,307,437,377,790, and the highest ZTS revenue forecast at $4,596,658,354,287.
In 2025, ZTS is forecast to generate $4,756,497,744,973 in revenue, with the lowest revenue forecast at $4,700,336,069,575 and the highest revenue forecast at $4,812,659,420,370.